Approval · Notice of Compliance 35821 · 2025
ANDEMBRY: Notice of Compliance 35821
Issued August 6, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35821
- Date
- August 6, 2025
- Company
- Csl Behring Canada IncOttawa, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- GARADACIMAB 200 MG per 1.2ML